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Summary A B16 mouse melanoma cell line resistant to doxorubicin was obtained by continuous in vitro
exposure to the drug. The ID50 for this line was 200 times higher than that for the parental cell line. The
resistant cell line had some biological characteristics similar to those of the sensitive parental cell line, like
saturation density and protein content. Differences were found in doubling time which was longer, cloning
efficiency which was lower and DNA content which was higher in the resistant as compared to the parental
line. Intracellular distribution of doxorubicin was also different having a nuclear-cytoplasmic ratio higher in
sensitive than in resistant cells. Melanin content was an unstable feature in the sensitive cell line, whereas
melanin was always present in resistant cells. Resistance to doxorubicin was maintained during 50 in vitro
passages in the absence of the drug. Cross-resistance was found with vincristine and other anthracyclines, like
daunorubicin and 4'-epi-doxorubicin but not with cis-platinum, and a new doxorubicin derivative, 4'-deoxy-
4'-iodio-doxorubicin. The B16 line showed a lower resistance index to 4'-deoxy-doxorubicin and 4-demethoxy-
daunorubicin (30 and 3 respectively), as compared to doxorubicin. Doxorubicin-resistance was partially
circumvented by pretreatment of resistant cells with verapamil, a calcium chelating agent, and by
trifluoperazine, a calmodulin-antagonist.
Doxorubicin (DX) is among the most widely used
cytotoxic agents because it is active on different
kinds of human tumours (Bonadonna et al., 1975;
Davis & Davis, 1979). One limitation in its use,
however, is the emergence of drug-resistance in the
tumours under treatment (Kaye & Merry, 1985).
The development of resistance to drugs is a
common clinical problem in the treatment of
various cancers but the mechanisms responsible for
its appearance are still not fully understood. It is
also unknown whether the resistance is a
characteristic of a cell subpopulation of the original
tumour or it is induced by the treatment itself.
Human malignant melanoma is unresponsive to
chemotherapy because of the emergence of sub-
populations of resistant cells (Gaukroger et al.,
1982). On the contrary, the mouse melanoma B16
is sensitive to DX treatment (Goldin et al., 1981).
In order to study the mechanisms of drug
resistance, we selected a cell line of B16 melanoma
with elevated levels of resistance to DX by
continuous in vitro exposure to increasing
concentrations of the drug. The DX-resistant and
DX-sensitive cell lines were then characterized for
different biological parameters in order to
understand the possible basis of their different
chemosensitivity. A calcium chelating agent and a
calmodulin antagonist were used to circumvent
drug resistance which was also challenged with
some DX analogs, vincristine (VCR) and cis-
diamminedichloroplatinum II (cis-DDP).
Materials and methods
Drugs
DX, daunorubicin (DNR), 4'-epi-DX, 4'-deoxy-
DX, 4'-deoxy-4'-iodio-DX, 4-demethoxy-DNR and
cis-DDP were a gift from Farmitalia-Carlo Erba
(Milan, Italy). VCR was purchased from Eli-Lilly
(Indianapolis, IN, USA). Verapamil was purchased
as Isoptin by Knoll AG Liestal (Switzerland); tri-
fluoperazine was obtained by Maggioni (Milan,
Italy). All drugs were dissolved in distilled water
immediately before use.
Cell lines
A B16 melanoma cell line (B16V) was obtained by
mechanical disaggregation of a B16 melanoma
tumour grown in syngeneic C57BL/6 mice. Cells
were transferred in tissue culture in RPMI 1640
medium (Flow Laboratories, Irvine, Ayrshire, UK)
containing 10% foetal calf serum (FCS) (Flow
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Laboratories), antibiotics and Fe(CN)6K3 0.03mm
as reported by Ellem & Kay (1983); cells were
subcultured twice a week. After 5 in vitro passages,
an aliquot of cells was grown in the presence of
5ngml -1 DX; drug concentration in the culture
medium was then increased by 10ngml-1 every 1
or 2 weeks. This cell line was designated
B16VDXR.
Cytotoxicity experiments
Tumour cells (2 x 105ml-1) were seeded in
complete culture medium in 6-well Costar tissue
culture cluster (Costar, Cambridge, Mass, USA)
and treated at cell seeding with different drug
concentrations in replicate samples. After 72h, cells
were harvested with trypsin-EDTA and counted in
a Coulter Counter (ZBI, Electronics, Luton, UK);
cell viability was determined by trypan blue dye
exclusion. The resistance index (RI) was the ratio
between the dose inhibiting the 50% (ID50) of the
growth of B16VDXR and the ID50 of B16V cells.
The ID50 was calculated from the curve of percent
cell survival at different concentrations of the drug.
In experiments performed in the presence of
verapamil or trifluoperazine, these drugs were
added to the culture medium at the same time of
cell seeding whereas DX was added 24h later;
experiments were stopped 72h after cell seeding.
Doubling time and cloning efficiency
The doubling time was obtained from the diagram
of growth curves of B16V and B16VDXR cell lines
by evaluating the time necessary for the population
in logarithmic phase to double the cell number.
For the evaluation of cloning efficiency, 400 cells
of B16V and B16VDXR were seeded in 5cm Petri
dishes (Falcon, Becton Dickinson, CA, USA). After
7 and 10 days respectively, cells were fixed with
methanol and stained with crystal-violet. Colonies
of at least 20 cells were counted with an inverted
microscope.
The mean cell diameter was obtained by counting
40 cells from a suspension obtained by trypsinization
under a microscope with a calibrated eyepiece
micrometer.
Melanin determination
Cells were harvested with trypsin-EDTA and
collected in saline solution. Aliquots of cells were
counted and protein concentration determined by
the method of Lowry et al. (1951). The remaining
fraction used for melanin quantitation (Meyskens &
Fuller, 1980) was resuspended in 1 ml of NaOH IN
and DMSO 10% and kept at 37°C for 60min.
Samples were read on a Beckman spectro-
photometer at wavelength 470nm.
Flow cytometric determination ofDNA content
Cells harvested with trypsin-EDTA were washed in
PBS and resuspended in a solution of 0.1% sodium
citrate containing 50 ugml-1 propidium iodide
(Calbiochem-Behring Corp., La Jolla, CA, USA),
50Uml-1 RNAse A (Sigma, St Louis, MO, USA)
and 0.05% triton X-100 (Calbiochem-Behring
Corp.). Mouse thymocytes used as references of the
diploid value, were processed in the same way.
Flow cytometric measurements were performed
with a microscope-based flow cytofluorimeter
(Leitz, Wetzlar, West Germany), equipped with a
100WHg lamp as the source of excitation light.
Excitation and emission wavelengths were selected
by a BG38 and a BG 12 excitation filters, a 580nm
chromatic beam splitter and a 610nm barrier filter.
Fluorescence intensity, proportional to DNA
content, was recorded by a multichannel analyzer
(Spectrascope Modular 8000, Laben, Milan, Italy)
and displayed as fluorescence histograms.
Intracellular distribution studies ofDX.
Intracellular distribution of DX was studied in cell
monolayers grown on coverslips, incubated with the
drug for 0.5, 24 or 48 h. At the end of the
incubation, the coverslips were rinsed with PBS and
mounted upside down on microscopic slides. The
fluorescence intensity of anthracycline was analyzed
subsequently in the nucleus and in the cytoplasm of
each cell by performing spot measurements with a
2,pm diameter diaphragm. Measrurements were
performed by a Leitz MPV2 microscope-
photometer, equipped with an automatic device for
correction of lamp fluctuations (Freitas et al.,
1981), with a 95X oil immersion objective
(NA 1.32). Excitation light was supplied by a xenon
lamp XBO75W, and selected by excitation filters
BG38(4mm), BG 12 (1.5mm) and chromatic beam
splitter 495nm. Emission light was collected by a
barrier filter K 570. Quenching of nuclear
fluorescence was considered not to affect the
measurements significantly, since a linear
relationship between fluorescence intensity and
intracellular concentration has been reported (Speth
et al., 1985).
Results
Induction and level ofDX resistance in B16 cells
The resistant variant cell line (B16VDXR) was
obtained by continuous in vitro treatment of
parental cells (B16V) with increasing concentrations
of DX in the culture medium. As shown in Table I,
the treatment induced increasing values of RI,
without reaching a plateau up to a DX dose ofDOXORUBICIN-RESISTANT B16 MELANOMA LINE
Table I Resistance index of B16VDXR cell line after cultivation in the
presence of different concentration of doxorubicin
Passage Doxorubicin Doxorubicin Resistance
Cell line number (ngml 1)a ID50 (ngml ') index
B16V 15-80 0 11+ 1.9
B16VDXR 20 100 330 30
27 200 550 50
35 290 693 63
45 350 1700 154
61-98b 420 2200+200 200
78 600 3050 277
96 700 3650 322
105 860 4800 436
aConcentration in the culture medium; bCells were continuously kept in
420ngml-' of DX from the 61st throughout the 98th passage.
860ngml -1, when the RI was 436. Higher
concentrations of DX were not tested. The RI of
200 remained stable by maintaining cells for at least
37 passages (passage 61 to 98) in the presence of a
constant drug concentration.
In all the experiments reported throughout this
paper only cells maintained in the presence of
420ngml 1 of DX and showing a RI of - 200
were used.
To see whether the duration of treatment affects
the outcome of the RI, B16V and B16VDXR (RI
200) lines were treated for 1, 24 or 72h with DX
and their ID50 and RI evaluated. As shown in
Table II, the RI is not dependent on the duration
of treatment, since exposure of cells for 1, 24 or
72h to different concentrations of drug resulted in
a different ID50 but in a similar RI. The ID50 after
24h of treatment was 10 times lower compared to
the corresponding ID50 after 1 h, and a further
reduction of about a factor of 2 was evident after
72 h of treatment. Taking into account these results,
in the subsequent cytotoxicity experiments cells
were always exposed to drugs for 72h.
To see whether by increasing DX concentrations
all tumour cells were killed, the pattern of
sensitivity of both B16V and BI6VDXR to
increasing doses of DX was investigated. Figure 1
shows the results of this experiment. DX was
Table II Cytotoxicity of doxorubicin on B16V and
B16VDXR cell lines after different time of exposure
ID50(ngml-1)
Time of Resistance
exposure (h) B16V B16VDXR index
1 190 40,000 210
24 19 4,000 210
72 11 2,200 200
0
L-
0
4-- 100-
0
, 80
16 60-
2 40-
"' 20-
a) 0
{444
1 10 100 1000 10000 100000
Doxorubicin (ng ml-')
Figure 1 Cytotoxicity of DX
B16VDXR cell lines. Mean of
+s.d.; A B16V; A B16VDXR.
on B16V and
four observations
cytotoxic on the sensitive cell line with
concentrations ranging from 4 to 60ngml 1. At
doses one logarithm higher, no increase in
cytotoxicity was observed and 20% cells could
survive in spite of the high DX concentrations.
B16VDXR cell line shows a survival curve with the
same slope, DX being cytotoxic from 800 through
6000ngml-1. Between 6000 and 60000ngml-1,
similar to that observed on B16V cells, -20% of
the cells were resistant to DX treatment. From
these results it can be concluded that in the
sensitive B16V cell line a subpopulation of cells is
present which can resist doses of DX 80 times
higher than the ID50 of the whole population.
Thus, the B16VDXR line might be the result of
selection of this subpopulation.
In the B16VDXR cell line too, a fraction of cells
resistant to concentrations of DX at least one
logarithm higher than the ID50 was evident.
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Characteristics ofB16V and B16VDXR cell lines
Several biological characteristics of the two lines
(B16V and B16VDXR) are reported in Table III.
Significant differences between the two cell lines
could be observed, the doubling time being longer
and the cloning efficiency lower in the resistant as
compared to the parental line. The amount of
protein, the cell diameter and the melanin content
per cell evaluated at the stationary phase were
slightly higher with lower variability in the resistant
compared to the sensitive cell lines. The cell shape
of detached cells was heterogeneous in B16V cells,
whereas it was round in B16VDXR cells.
We want to point out that when cells started to
grow in the presence of DX, it was evident from
microscopical observations that the drug induced
an increase of cellular volume and of pigmentation.
With progressive subcultivations we observed that
whereas in the sensitive line the melanin content
was going up and down as already reported for B16
melanoma cells grown in vitro (De Pauw-Gillet et
al., 1985) in the resistant line this content was
stable. The saturation density of the two cell lines
evaluated at the stationary phase was similar.
Stability ofresistance.
To assess the stability of drug resistance in our cell
line, B16VDXR cells were subcultured in complete
medium without DX for about 9 months (i.e. for
50 passages) and the sensitivity to DX was assayed
at different passages (Figure 2). No significant
changes in the ID50 nor in the slope of the dose-
response curves were noted throughout the
observation time. Thus, DX-resistance of the
B16VDXR cell line seems to be a stable phenotype.
Determination ofDNA content.
The histograms of fluorescence intensity (propor-
tional to the DNA content) of sensitive (a) and
resistant (b) B16 melanoma cells, are shown in
Figure 3, together with the fluorescence distribution
100-
> ,, 80-
8 60-
QQ
-o
00
50 100 500 1000 5000
Doxorubicin (ng ml-')
Figure 2 Maintenance of drug-resistance in
B16VDXR cell line cultured in absence of DX; A 10th
passage without DX (7 weeks); A 20th passage
without DX (16 weeks); * 30th passage without DX
(26 weeks); 0 40th passage without DX (33 weeks); 0
50th passage without DX (41 weeks).
of mouse thymocytes (c) measured for reference to
the diploid value.
B16V cells show a bimodal fluorescence
distribution where the first peak is similar to the G1
diploid value of thymocytes, while the second peak
has the position of cells in G2 +M phase. The
resistant cells show a first peak similar to that of
sensitive cells; cells with a fluorescence value
corresponding to the G2 +M phase are present only
in a small percentage, while a third peak shifted
towards higher values (hypertetraploid) is found. It
is evident that cells with intermediate values
between the two peaks, i.e. of cells in S phase, are
practically absent in both cell lines.
Intracellular distribution ofDX
In order to understand whether cellular resistance
could be due to a different intracellular distribution
of the drug, experiments aimed at evaluating DX
distribution in the cells with a microscope-
photometer were performed. Data reported in
Table-IV show that at different times of treatment
and with different concentrations of drug, the
nuclear/cytoplasmic ratio of DX fluorescence was
Table III Characterization of B16V and B16VDXR cell lines
Tumour cell lines
Characteristics B16V B16VDXR
Doubling time (h) 15 + 1.64 25 + 1.71
Cloning efficiency (%) 60 7
Proteins (pg)/106 cells 309+42 388+45
Melanin (OD470)/106 cells 0.038+0.016 0.070+0.013
Cell density at stationary phase cm2 159+40( x 103) 137+23( x 103)
Cell diameter (,um) 20.4+4.0 26.7+ 1.9
Cell shape in detached cells Heterogeneous RoundDOXORUBICIN-RESISTANT B16 MELANOMA LINE 37
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Figure 3 Distribution of fluorescence intensity of
DNA-propidium iodide in melanoma sensitive and
resistant cells. (a) B16V: peaks at channel 103 and 205;
(b) Bl6VDXR: peaks at channel 100, 197 and 257; (c)
Mouse thymocytes: peaks at channel 96 and 188.
higher in sensitive than in the resistant cells. Other
authors (Speth et al., 1985) reported that in these
conditions quenching of fluorescence is minimal.
Since quenching is a nuclear phenomenon it is
possible that values of nuclear but not of
cytoplasmic fluorescence are underestimated.
Nevertheless, for long term treatments (48h) the
nuclear/cytoplasmic fluorescence ratio was lower
around value of unity for both cell lines.
Multi-drug resistance.
Pleiotropic drug-resistance has been reported for
many different cell lines (Kaye & Merry, 1985). We
tested, therefore, whether B16VDXR cells were
sensitive to the cytotoxic action of other
anthracyclines and of anticancer drugs having
Table IV Intracellular distribution of doxorubicin in
B16V and B16VDXR cells
Nuclear/cytoplasmic ratioa
Doxorubicin B16V B16VDXR
l0,gm-' x 30min 4.83 + 1.50b 2.55+0.78
1ugml-'x 24h 2.44+0.68b 1.56+0.46
ljpgml-' x48h 0.87+0.08 0.82+0.13
24h after the cell seeding DX was added to the culture
medium. After different times of exposure fluorescence was
measured as described in Materials and methods; aMean of
at least 10 samples for each point; "P<0.01 according to
Student's t test.
different mechanisms of action like VCR and cis-
DDP. The anthracycline derivatives chosen were 4'-
epi-DX, 4'-deoxy-DX, DNR and 4-demethoxy-
DNR which have been already used in clinical trials
(Ferrari et al., 1984; Kaplan et al., 1984; Holdener
et al., 1985), and 4'-deoxy-4'-iodio-DX, because it
has been shown to be active on the DX-resistant
P388 cell line (Facchinetti et al., 1984). VCR, a
typical DX cross-resistant drug (Wilkoff &
Dulmadge, 1978), and cis-DDP, a non DX cross-
resistant drug (Seeber et al., 1982), were also tested.
The results are shown in Figure 4. 4'-Epi-DX
(Figure 4A) appears to display complete cross-
resistance with DX.; 4'-deoxy-DX (Figure 4B) has a
lower RI compared to DX (30 vs. 133), whereas 4'-
deoxy-4'-iodio-DX (Figure 4C) is not cross-
resistant, being cytotoxic to the same extent on
both cell lines. As reported on several other DX-
resistant cell lines (Wilkoff & Dulmadge, 1978),
DNR showed cross-resistance with DX also on the
B16VDXR line (Figure 4D), whereas its derivative
4-demethoxy-DNR (Figure 4E) was more active
having a RI of 3. Cross-resistance of B16VDXR
with VCR was also evident (Figure 4F), while cis-
DDP (Figure 4G) resulted in a higher activity (2-
fold) on B16VDXR than on B16V cells.
It is interesting to observe that in the sensitive
line the dose-response curve of cells treated with
DX and VCR shows a rapid fall at doses up to 40
and 8ngml-1 respectively, where a shoulder is the
beginning of a plateau of activity which persists for
drug concentrations - 2 logarithmic units higher
with 10-20% of surviving cells. On the same cell
line the other DX-derivatives tested and also cis-
DDP show a dose-dependent cytotoxicity which
reaches, with different slopes, 100% of cell growth
inhibition. For these drugs, therefore, no
correlation can be found between RI and slope of
activity.
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Figure 4 Cytotoxicity of different drugs on Bl6V and B16VDXR cell lines. Mean of four observations +s.d.
Open symbols refer to Bl6V and closed symbols refer to B16VDXR line. In each panel triangles refer to cell
survival after treatment with DX and the remaining symbols to treatment with the indicated drug. A, 4'-
epiDX; B, 4'-deoxy-DX; C, 4'-deoxy-4'-iodio-DX; D, DNR; E, 4-demethoxy-DNR; F, VCR; G, cis-DDP.
Circumvention ofresistance by a calcium-chelating
agent and a calmodulin-antagonist
Experiments were then carried out with verapamil
(a calcium-chelating agent) and trifluoperazine (a
calmodulin-antagonist) in an attempt to circumvent
drug resistance. Table V shows that the addition of
10 M of verapamil 24h before treatment and its
presence during treatment induces in B16V cells a
5-fold increase of drug activity. In the B16VDXR
cell line the same treatment enhances DX activity
leading to a RI of 5 instead of 166 obtained in the
absence of verapamil. Lower concentrations of the
calcium-antagonist have a reduced effect, but
significant at the highest doses of DX tested.
As with verapamil, treatment with trifluoperazine
was started 24h before the addition of DX. The
results of Table VI indicate that treatment with
8 gM trifluoperazine does not affect the activity of
the drug on B16V cell line, while it enhances the
activity of DX on B16VDXR cell line where the
ID50 of the anthracycline is reduced 16-fold. The
circumvention of DX-resistance is correlated with
the concentration of trifluoperazine in the culture
medium since with 1.6 gM trifluoperazine, the ID50
of DX is reduced only about 2-fold.
Discussion
Human malignant melanoma is a tumour resistant
to different chemotherapeutic drugs including DX.
It is unknown whether resistance is primary, that is
intrinsic to malignant cells, or acquired upon drug
treatment through mutation and/or cellular
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Table V Effect of verapamil on doxorubicin cytotoxicity on B16V and B16VDXR cell lines
Cell survival (% ofcontrol +s.d.) with thefollowing DX doses (ngml 1)
Verapamil 0 1.6 8 40 200 1000 5000 ID50a RIb
B16V
None 88+5.4 62+ 5.6 28+3.1 22+4.5 - 12
1UM 94+5.8 82+4.7 39+6.3c 19+4.2c 18+5.1 - 7.8
10pM 91+ 1.5 55+ 1.3c 25+ 3.6c 17+4.5 22+55 -0 2.3
B16VDXR
None 103+4.5 95+5.6 70+8.2 30+5.2 2000 166
1pM 103+5.2 100+3.2 91+8.9 34+4.1c 19+2.3c 620 52
10pM 94+3.0 58+ 10.6c 32+7.2c 21 +0.7c 7+2.7c 60 5
aCalculated by the curve of the percent of survival cells at different concentrations of verapamil;
bEvaluated as the ratio between the ID50 of DX at different concentrations of verapamil on B16VDXR
cells and the ID50 of DX on B16V cells; CP<0.01 according to Student's t test.
Table VI Effect of trifluoperazine on doxorubicin cytotoxicity on B16V and B16VDXR cell lines
Cell survival (% of control +s.d.) with the following DX doses
(ngml 1)
Trifluoperazine 0 8 40 200 1000 5000 ID50" RIb
B16V
None - 62+5.6 28+3.1 22+4.5 12
1.6,UM 98+10.1 73+5.1 31+4.2 26+2.1 19
8.0pM 90+6.1 47+7.2 30+5.1 24+3.6 8
B16VDXR
None - 103+4.5 95+5.6 70+8.2 30+ 5.2 2000 166
1.6,UM 104+3.2 103+3.1 100+4.3 48+6.1c 37+2.6 870 72
8.0,UM 90+8.3 - 85+5.0 36+6.1c 30+3.5c 17+2.2c 120 10
aCalculated by the curve of the percent of survival cells at different concentrations of
trifluoperazine; bEvaluated as the ratio between the ID50 of DX at different concentrations of
trifluoperazine on B16VDXR cells and the ID50 of DX on B16V cells; CP<0.01 according to
Student's t test.
selection. Regardless of the type of mechanism, it
has been observed that human melanoma cells
manifest immediate or very early resistance to
chemotherapy (Tanigawa et al., 1984).
On the contrary, transplanted murine B16
melanoma is responsive to DX treatment (Goldin et
al., 1981). The aim of the present work was to
induce a DX-resistant B16 cell line and to
characterize the mechanisms of drug-resistance in
these cells.
Our experiments have shown that it is possible to
obtain DX-resistant cells (Bi6VDXR) from an
originally drug sensitive B16 line (B16V) by
exposure to progressively increasing amounts of
DX. Naturally DX-resistant cells, however, are
likely to be present in the parental cell line since
even high dose treatment of B16V was never able to
kill 100% of cells, leaving 10-20% of tumour cells
surviving to DX concentrations 100 times higher
than the ID50 of the whole cell line. The same
effect was found by treating the B16VDXR line,
suggesting the possibility that cells could be
obtained with a RI even higher than that already
reached. In vitro selection of DX-resistant lines,
however, might not be representative of the clinical
situation. Although no direct comparison is
available between in vitro and in vivo generated
DX-resistant solid tumours, data obtained in vivo
with murine leukaemias and MT mouse mammary
carcinoma suggest that drug treatment eliminates
drug-sensitive cells which compose the majority of
the tumour leaving a pre-existing highly drug-
resistant cell subpopulation (Skipper et al., 1978;
McMillan et al., 1985).40 R. SUPINO et al.
Some biological characteristics were different in
these two B16 cell lines. The longer doubling time,
lower cloning efficiency and higher DNA content of
B16VDXR cells are features of resistant cells
already reported in other resistant cell lines
(Yanovich & Preston, 1984). A genetic basis for
resistance has been reported in other drug resistant
cell lines where the presence of double minutes and
homogeneous staining regions was observed (Kaye
& Merry, 1985); studies are in progress in
B16VDXR cells to further characterize the increase
in the content of DNA. Melanin content was
variable during the time of cultivation of our
sensitive line as already reported by other authors
(De Pauw-Gillet et al., 1985) but it became a
constant feature of B16VDXR cells. On the basis of
the observation of a slight but stable increase of
protein content, cell diameter and pigmentation and
of a higher variability of these features in sensitive
cells as compared with resistant cells, we can
hypothesize that DX treatments selected cells
already present in the parental cell line.
Nevertheless, as the increase of pigmentation is
considered an index of cell differentiation (Lotan &
Lotan, 1980; Meyskens & Fuller, 1980), it is also
possible that continuous DX treatment induced this
process in B16V cells, as previously suggested for
pleiotropic drug resistant CHO cells (Biedler et al.,
1975).
The different cell shape can be due to some
membrane alterations already observed in other
drug resistant cells lines (Peterson et al., 1983).
The difference in the intracellular distribution of
DX may be partially responsible for resistance since
our data indicate that at least in the first 24h the
nuclear/cytoplasmic ratio of DX content in Bl6V
cells was twice that of B16VDXR cells. This ratio
was reduced and became similar in both cell lines
after 48 h of culture in the presence of DX. Since
DX uptake on other cell lines is known to be
completed within 2h (Supino et al., 1977) these
data suggest that after 24 and 48h most of the drug
has left the nucleus. These results agree with the
observation of a disappearance of nuclear
fluorescence in colon cancer cells cultivated for 1
day or longer in the presence of DX (Chauffert et
al., 1984). Nevertheless, this higher nuclear
concentration of DX in sensitive cells compared to
resistant cells is insufficient to explain a RI of 200.
Thus, in this melanoma cell line further mechanisms
have to be responsible for drug resistance.
The maintenance of resistance of B16VDXR cell
line in the absence of DX indicates that, upon
continuous exposure to DX, a cell line was
obtained that had acquired a stable phenotype. In
fact, even after 50 passages in the absence of the
drug, the ID50 of DX was not significantly
reduced.
It is very interesting to note that between the
tested anthracyclines some were completely cross-
resistant with DX, like DNR and 4'-epi-DX, in
accordance with similar results reported on other
cell lines (Hill et al., 1985). Some anthracyclines
showed a low RI like 4-demethoxy-DNR (RI=3)
and 4'-deoxy-DX (RI=30) and these data too are
in accordance with experimental and clinical trials
(Ferrari et al., 1984; Kaplan et al., 1984; Hill et al.,
1985). 4'-Deoxy-4'-iodio-DX was cytotoxic on
B16VDXR to the same extent as that on B16V.
These findings, especially the lack of cross-
resistance between DX and 4'-deoxy-4'-iodio-DX,
might be important for future clinical trials with
these analogues. Since we discovered that resistance
to DX is associated with a different intracellular
distribution of the drug, it is possible that the same
phenomenon is involved in the resistance or the
sensitivity of B16VDXR cells to these anthra-
cyclines.
B16VDXR cell line is resistant to VCR and
sensitive to cis-DDP; The higher sensitivity of
B16VDXR to cis-DDP as compared to the sensitive
line suggests a collateral sensitivity which has been
also found with in vivo treatment of these two B16
lines (Formelli et al., submitted for publication).
This behaviour is similar to that of other DX-
resistant lines (Skovsgaard, 1978; Wilkoff &
Dulmadge, 1978; Seeber et al., 1982) and the
mechanisms of this phenomenon are at present
unknown.
Many authors have discussed the possibility of
circumventing DX- and VCR-resistance of different
cell lines by pretreatment of cells with calcium-
antagonists (Tsuruo et al., 1983; Kessel &
Wilberding, 1984; Kessel & Wilberding, 1985) or
calmodulin-inhibitors (Tsuruo et al., 1982;
Ganapathi & Grabowski, 1983). Also, resistance of
the B16 melanoma cell line could be reduced but
not completely antagonized in the presence of sub-
toxic concentrations of verapamil or trifluoperazine.
The activity of verapamil was shown to be dose-
dependent and more pronounced in B16VDXR
than in B16V cell line. The activity of trifluo-
perazine was also dose-dependent but it was present
only in B16VDXR cells where it induced a
reduction of ID50 of only 16 times compared to the
33-fold reduction caused by verapamil. We have
also observed that no alterations in DX cytotoxicity
was induced on either cell line by increasing
calcium-concentration up to subtoxic doses (8mM
and 2mM) in the culture medium (data not shown).
This may indicate that the effect of verapamil and
trifluoperazine on DX cytotoxicity is dependent not
only on alterations in calcium flux but also on
other mechanisms.
In conclusion, the results reported in this paper
indicate that this cell line can be a useful tool toDOXORUBICIN-RESISTANT B16 MELANOMA LINE 41
investigate further the cellular alterations associated
with drug resistance and to screen for drugs active
on DX-resistant cells and for studies on the
circumvention of DX-resistance.
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